AKBA Q4 2021 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$58M+1.7% YoY

Gross Profit

$26M45.0% margin

Operating Income

-$65M-113.3% margin

Net Income

-$70M-121.1% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

+18.3%

Cash Flow

Operating Cash Flow

-$63M

Free Cash Flow

-$63M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$529M

Total Liabilities

$455M

Stockholders' Equity

$74M

Cash & Equivalents

$150M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$58M	$57M	+1.7%
Gross Profit	$26M	$30M	-13.1%
Operating Income	-$65M	-$85M	+23.5%
Net Income	-$70M	-$87M	+19.7%

Revenue Segments

Product

$42M59%

License Collaboration And Other Revenue

$29M41%